By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.) 

9620 Medical Center Drive

Rockville  Maryland  20850  U.S.A.
Phone: 240-864-2600 Fax: 301-315-2437


Company News
ASCO2016: CASI Pharmaceuticals  (CASI) Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma (OCCC) 6/1/2016 11:26:25 AM
CASI Pharmaceuticals  (CASI) Reports First Quarter 2016 Financial Results 5/13/2016 7:44:33 AM
CASI Pharmaceuticals  (CASI) Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) 5/12/2016 10:01:35 AM
James E. Goldschmidt, Ph.D. Joins CASI Pharmaceuticals  (CASI) As Vice President Of Business Development 4/18/2016 7:20:37 AM
CASI Pharmaceuticals  (CASI) Reports 2015 Fourth Quarter And Full Year Financial Results 3/28/2016 6:20:22 AM
CASI Pharmaceuticals  (CASI) Announces Initial Closing Of Its Strategic Financing With Receipt Of $10.3 Million Proceeds 1/19/2016 6:44:08 AM
CASI Pharmaceuticals  (CASI)' Import Drug Registration Application For MARQIBO Accepted For Review By CFDA 1/12/2016 7:29:43 AM
CASI Pharmaceuticals  (CASI) Reports Third Quarter 2015 Financial Results 11/13/2015 8:24:35 AM
CASI Pharmaceuticals  (CASI) Release: Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-National Cancer Institute-EORTC International Conference 11/9/2015 6:55:06 AM
CASI Pharmaceuticals  (CASI) Release: Poster For ENMD-2076 Phase 2 Trial In Soft Tissue Sarcoma Presented At The 2015 Connective Tissue Oncology Society Annual Meeting 11/6/2015 6:22:10 AM